Abstract Calcium-independent phospholipase A 2 group VIa (iPLA 2 b) preferentially releases docosahexaenoic acid (DHA) from the sn-2 position of phospholipids. Mutations of its gene, PLA2G6, are found in patients with several progressive motor disorders, including Parkinson disease. At 4 months, PLA2G6 knockout mice (iPLA 2 b -/-) show minimal neuropathology but altered brain DHA metabolism. By 1 year, they develop motor disturbances, cerebellar neuronal loss, and striatal a-synuclein accumulation. We hypothesized that older iPLA 2 b -/-mice also would exhibit inflammatory and other neuropathological changes. Real-time polymerase chain reaction and Western blotting were performed on whole brain homogenate from 15 to 20-month old male iPLA 2 b -/-or wild-type (WT) mice. These older iPLA 2 b -/-mice compared with WT showed molecular evidence of microglial (CD-11b, iNOS) and astrocytic (glial fibrillary acidic protein) activation, disturbed expression of enzymes involved in arachidonic acid metabolism, loss of neuroprotective brain derived neurotrophic factor, and accumulation of cytokine TNF-a messenger ribonucleic acid, consistent with neuroinflammatory pathology. There was no evidence of synaptic loss, of reduced expression of dopamine active reuptake transporter, or of accumulation of the Parkinson disease markers Parkin or Pink1. iPLA 2 c expression was unchanged. iPLA 2 b deficient mice show evidence of neuroinflammation and associated neuropathology with motor dysfunction in later life. These pathological biomarkers could be used to assess efficacy of dietary intervention, antioxidants or other therapies on disease progression in this mouse model of progressive human motor diseases associated with a PLA2G6 mutation.
Introduction
In vertebrates, the polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA, 22:6n-3) is thought to play antioxidant, neuroprotective, and neurotransmission roles in brain [1] [2] [3] [4] . DHA must be obtained directly from the diet or by liver synthesis from its dietary essential precursor, a-linolenic acid (a-LNA, 18:3 n-3) [5] . It is found in high concentrations in the sn-2 position of brain membrane phospholipids, from where it can be released preferentially by a calcium-independent phospholipase A 2 , iPLA 2 b or iPLA 2 c [6, 7] . iPLA 2 b accounts for 70 % of cytosolic PLA 2 activity in rat brain [6, 8] . Mutations in its gene, PLA2G6, occur in infantile neuroaxonal dystrophy (INAD) [9, 10] , neurodegeneration with brain iron accumulation (NBIA) [10, 11] , early-onset dystonia-parkinsonism [12] [13] [14] , and Parkinson disease [15] . iPLA 2 b knockout mice have been developed to understand the consequences of these mutations [16, 17] .
iPLA 2 b plays a role in motor behavior, since injection of the iPLA 2 b inhibitor bromoenol lactone (BEL) into the rat striatum, thalamus, or motor cortex produces chewing movements [18] . Furthermore, iPLA 2 b -/-mice exhibit age-dependent motor dysfunction associated with axonal degeneration and spheroids in the central nervous system by 1 year of age [16, 19] . Similar axonal swelling with spheroids occurs in the central and peripheral nervous systems of INAD and NBIA patients. Thirteen month-old iPLA 2 b -/-mice also show cerebellar atrophy with Purkinje cell loss, increased levels of inflammatory cytokines, glial cell activation, and striatal accumulation of a-synuclein [16, 20] .
To characterize progressive age-related neuropathology in iPLA 2 b -/-mice, we first studied brain PUFA metabolism in 4-month old mice with normal motor function and minimal brain spheroid accumulation [4, 21] . Compared to wild-type (WT) controls, these mice exhibited disturbances in brain DHA metabolism that included reduced esterified brain DHA concentration in ethanolamine and serine glycerophospholipids, reduced DHA incorporation rate from plasma into brain phospholipids at rest or during cholinergic activation, and disturbed fatty acid concentrations in lysophospholipids. In addition, their brains showed increased expression of enzymes involved in arachidonic acid (AA, 20:4n-6) metabolism, including cytosolic cPLA 2 -IVa (cPLA 2 a), secretory sPLA 2 -V and cyclooxygenase (COX)-2 [8, 22] .
In the present follow-up study, we measured expression of a number of brain parameters in 15 to 20-month old iPLA 2-b -/-mice and in WT mice. These included: (1) enzymes involved in AA metabolism [cPLA 2 a, sPLA 2 -V, COX-2, COX-1, and microsomal prostaglandin synthase (mPGES) [22] An abstract of part of this work has been published (Society for Neuroscience Meeting, New Orleans, LA, 2012).
Materials and Methods

Animals
Experiments were conducted in accord with the National Institutes of Health guidelines for the Animal Care and Use Committee (Publication no. 86-23) and followed a protocol approved by the Animal Care and Use Committee of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Male iPLA 2 b -/-mice and their WT littermates [23] were housed in an animal facility having regulated temperature, humidity and light cycle until they reached 15-20 months of age. They had free access to water and to a diet (PicoLab Ò Rodent Diet 20, 5053, LabDiet, Richmond, IN) containing (as % total fatty acid): 20.0 % saturated, 22.2 % monounsaturated, 47.7 % linoleic acid, 5.1 % linolenic acid, 0.1 % AA, 0.2 % eicosapentaenoic acid and 0.9 % DHA. Mice (n = 8 per group) were asphyxiated by CO 2 inhalation and decapitated, and their brains were rapidly excised and frozen in 2-methylbutane at -50°C and stored at -80°C for subsequent analyses.
Gene Expression
Half brains were homogenized with an Ultraturax homogenizer (IKA Works, Wilmington, DE) in QIAzol lysis reagent (Qiagen, Valencia, CA) and mRNA was isolated with a phenol-chloroform extraction method using the RNeasy Lipid tissue kit (Qiagen). Total mRNA was reverse-transcribed to cDNA according to the manufacturer's instructions with a high capacity cDNA Archive kit (Applied Biosystems, Carlsbad, CA). Gene expression was determined by real time-polymerase chain reaction (RT-PCR) using the Taqman Ò Universal PCR Mastermix and specific Taqman Ò primers and probe (Applied Biosystems). The PCR reaction was performed in duplicate, using ABI Prism 7000 sequence detection system (Applied Biosystems) as follows: 2 min at 50°C, 5 min at 95°C, 40 cycles of 10 s at 95°C, and 1 min at 60°C. Relative gene expression was determined using the DDCt method, using the 18S gene expression for normalization.
Protein Extraction
Half-brains were homogenized in a buffer containing 10 mM HEPES, pH 7.5, 1 mM EDTA, 0.34 M sucrose and protease inhibitors (Complete EDTA-free, Roche Applied Science, Indianapolis, IN), using a Dounce glass homogenizer (Thomas Scientific, Swedesboro, NJ). After ultracentrifugation (100,000g, 1 h, 4°C), the supernatant was used as the cytosolic fraction. The pellet was resuspended in Tris 20 mM, pH 7.4 containing 0.2 % Triton X-100 for 1 h at 4°C under agitation. The sample was centrifuged (100,000g, 1 h, 4°C) and the resulting supernatant contained the membrane fraction. Protein concentrations in the cytosolic and membrane fractions were determined with a Bradford assay [24] and samples were stored at -80°C until analyzed.
Protein Analysis
Cytosolic or membrane proteins (20 lg) were separated by SDS-PAGE in 4-20 % Tris-HCl polyacrylamide gels (BioRad, Hercules, CA) and transferred on a nitrocellulose membrane (Bio-Rad) for immunoblotting. Membranes were blocked for 90 min at room temperature with a caseinbased blocking buffer (Sigma Aldrich, St Louis, MO) before incubation overnight at 4°C with primary antibodies. Cytosolic proteins were probed with specific antibodies for cPLA 2 a (1:500), sPLA 2 (1:1,500) (ProteinTech, Chicago, IL) and DAT (1:1,000) (Millipore, Billerica, MA). All samples were probed with a b-actin antibody (Sigma Aldrich). Parkin expression was determined in the cytosol and membrane fractions (1:2,000, AbCam). Membranes then were incubated for 90 min at room temperature with the appropriate horseradish peroxidase-conjugated secondary antibodies (Bio-Rad), and peroxidase activity was determined by chemiluminescence using the SuperSignal West Pico reagents (Thermo Fisher Scientific, Rockford, IL). Relative protein expression was determined after normalization with the b-actin expression using ImageJ software [25] . TNF-a protein was quantified from 100 lg of brain cytosolic extract using an enzymelinked immunosorbent assay (ELISA) method according to the manufacturer's instruction (Thermo Fisher Scientific).
Statistical Analyses
Data are expressed as mean ± SEM (n = 7-8 per group). A two-tailed, unpaired t test using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA) was used to determine statistical significance, when P \ 0.05. Cohen's d effect size was used to interpret differences between the means when the P value was between 0.05 and 0.2, since this suggested increased risk of type II error associated with the small number of animals available for the study. An effect size is considered small if 0.3 \d \ 0.5, medium if 0.5 \d \ 0.8 and high if d [ 0.8 [26] . We considered effect sizes greater than 0.5 likely to be significant. Outliers were identified using Grubb's test and removed from the statistical analysis.
Results
Brain AA and DHA Metabolism iPLA 2 b protein expression was not measured in this study but iPLA 2 b deficiency was confirmed in the iPLA 2 b -/-mice by the virtual absence of brain iPLA 2 b mRNA compared to WT mice (P \ 0.001; Fig. 1 ), whereas the iPLA 2 c mRNA level did not differ between genotypes (Fig. 2c) . cPLA 2 a mRNA and protein levels were similar between groups, but the protein level of the activated phosphorylated form of cPLA 2 a in the membrane fraction was significantly higher for iPLA 2 b -/-compared to WT mice (51 %, P = 0.04) (Fig. 2a) . Although sPLA 2 -V mRNA also was higher (64 %, P = 0.02), sPLA 2 -V protein did not differ significantly between genotypes (Fig. 2b) . COX-1 mRNA and protein and COX-2 mRNA also did not differ between genotypes (Fig. 3a) , while COX-2 protein was reduced in iPLA 2 b -/-mice (12 %, P = 0.03) (Fig. 3b) . Brain mPGES mRNA was significantly higher in iPLA 2 b -/-mice, but mPGES protein did not differ between genotypes (Fig. 3c) . Protein levels of Acsl-6, MBOAT7, LPEAT2 and 15-LOX also did not differ between iPLA 2 b -/-and WT mice (Fig. 4) .
Neuroinflammation and Synaptic Loss TNF-a mRNA was increased 2.1-fold (P \ 0.001) in iPLA 2 b -/-mice compared to WT, but TNF-a protein levels were similar in both groups (Fig. 5a ), as were levels of IL-1b mRNA and protein (Fig. 5b) . iNOS mRNA and -/-mice. mRNA was quantified in duplicate with Taqman Ò RT-PCR using the DDCt method and normalization to 18S expression. Results are expressed as mean ± SEM (n = 8). ***P \ 0.001 (t test) protein did not differ significantly on t tests (P = 0.07 and 0.14 respectively), but their effect sizes measured as Cohen's d were large, 0.99 and 0.98 respectively (Fig. 5c) .
CD11b mRNA and protein levels were significantly higher in iPLA 2 b -/-mice compared to WT (60 and 30 %, P \ 0.05, respectively) (Fig. 6a) , suggesting microglial activation [27] . GFAP mRNA was elevated 2.2-fold (P \ 0.01) in iPLA 2 b -/-mice, but its protein level did not differ significantly between genotypes on t-tests (P = 0.19); nevertheless, Cohen's d test suggested a modest increase (d = 0.68) in iPLA 2 b -/-mice (Fig. 6b) . Protein levels of pre-synaptic synaptophysin and post-synaptic drebrin and PSD95 did not differ between genotypes (Fig. 6c) , while BDNF protein was reduced in iPLA 2 b -/-mice (22 %, P = 0.01) (Fig. 6d) .
Parkinson Disease Markers
Protein levels of both reduced DAT (50 kDa) and nonreduced DAT (75 kDa) did not differ between iPLA 2 b -/-mice and WT mice (Fig. 7) . Alpha-synuclein mRNA was significantly higher (53 %, P = 0.01), but a-synuclein protein (Fig. 8a), Pink1 (Fig. 8b) and Parkin (Fig. 8c) mRNA and protein did not differ between groups.
Discussion
These results indicate that long-term disruption of brain DHA metabolism in aged mice due to the absence of PLA2G6 results in microglial and astrocytic activation, -/-mice. mRNA was quantified in duplicate with Taqman Ò RT-PCR using the DDCt method and normalization to 18S expression. Results are expressed as mean ± SEM (n = 8). cPLA 2 a and sPLA 2-V protein was measured in brain cytosol and P-cPLA 2 a was quantified in the membrane fraction by Western blot. Results are normalized to b-actin expression (representative immunoblot is displayed) and expressed as % of the WT mice as mean ± SEM (n = 8, except n = 7 for P-cPLA 2 in iPLA 2 b -/-because an outlier value of 7.4 was removed). Numbers in italics indicate molecular weight markers (in kDa), NS : non-specific band. *P \ 0.05 (t-test) Neurochem Res (2014) 39:1522-1532 1525 Fig. 3 Expression of COX-2 (a), COX-1 (b) and mPGES (c) in WT and iPLA 2 b -/-mice. mRNA was quantified in duplicate with Taqman Ò RT-PCR using the DDCt method and normalization to 18S expression. Results are expressed as mean ± SEM (n = 8). COX-2, COX-1 were measured in brain cytosol and mPGES in the membrane fraction by western blot and normalized to b-actin expression (representative immunoblot is displayed). Results are expressed as % of the WT mice as mean ± SEM (n = 8, except n = 7 for COX-1 protein in WT due to an outlier value of 198 -/-). Numbers in italics indicate molecular weight markers (in kDa). *P \ 0.05, **P \ 0.01 (t test) -/-mice. The large effect sizes of increments in iNOS mRNA and protein and in TNF-a mRNA (and protein by Cohen's d), and increased CD11b mRNA and protein, suggest microglial activation by age 15-20 months [27] . Motor function was not assessed in the present study, but these neuropathological markers might be associated with appearance of age-dependent motor abnormalities in iPLA 2 b -/-mice reported by others [16, 19] . The lack of change in IL-1b levels suggests that full-blown global inflammation is not reached at this age and may require more time to evolve. On the other hand, Purkinje cell loss, glial cell activation and elevated TNF-a and IL-1b expression have been reported in the cerebellum of iPLA 2-b -/-mice at age 13 months [20] . The many late-appearing neuropathological changes in the iPLA 2 b -/-mice suggest that early defective DHA metabolism can contribute to human diseases that result from PLA2G6 mutations, such as INAD, neurodegeneration with brain iron accumulation, and early onset-dystonia parkinsonism (see 'Introduction'). Thus, this mouse model might be used to develop therapy for these diseases. Since iPLA 2 b has an anti-oxidant function that protects mitochondria from peroxidation damage [17] , one therapeutic approach with the model would be to administer antioxidants, as recommended for Parkinson disease [17, 28, 29] . Feeding DHA has been considered in this regard [2] , but the mice already were on a high DHA diet. On the other hand, an AA-free diet low in linoleic acid (18:2n-6) might be help to dampen the upregulated AA-metabolizing enzymes in the iPLA 2 b -/-mouse brain [30] [31] [32] . Unesterified DHA is preferentially acylated by Acsl-6 to DHA-CoA [33] , which can be reacylated into a lysophospholipid by an acyl-CoA lysophospholipid acyltransferase [34] . Within this latter enzyme family, we analyzed expression of MBOAT7, which recognizes AA-CoA as a substrate [35] , although its activity toward DHA-CoA remains to be tested. We also measured LPEAT2, which preferentially acylates ethanolamine glycerophospholipid enriched with DHA [36, 37] . The incorporation rate of unesterified DHA into brain ethanolamine glycerophospholipids and their DHA content are reduced in 4-month old iPLA 2 b -/-mice [4, 21] , but we found no significant difference between genotypes in brain expression of these acyltransferases or of 15-LOX, which is also involved in DHA metabolism [38] .
Reduced DHA incorporation from plasma into brain in iPLA 2 b -/-mice would be expected to reduce production of DHA-derived resolvin D1 and neuroprotectin D1, which have potent anti-inflammatory properties [39, 40] . DHA also may reduce pro-inflammatory AA metabolite production by inhibiting COX-2 [1, 41] , consistent with the suggested role of iPLA 2 b in regulating prostaglandin E 2 formation [7] . It would be worthwhile to test whether -/-mice. mRNA was quantified in duplicate with Taqman Ò RT-PCR using the DDCt method and normalization to 18S expression. Results are expressed as mean ± SEM (n = 8). An ELISA assay was used to quantify cytosolic TNF-a. Il-1b and iNOS protein was measured in brain cytosol by Western blot and normalized to b-actin expression (representative immunoblot is displayed). Results are expressed as % of the WT mice as mean ± SEM (n = 8, iNOS n = 6 for WT and n = 7 for iPLA 2 -/-due to unquantifiable signal). Numbers in italics indicate molecular weight markers (in kDa), NS non-specific band. ***P \ 0.001 (t test) and The elevated brain levels in iPLA 2 b -/-mice of sPLA 2 -V mRNA and P-cPLA 2 a protein, which represents the catalytically active form of cPLA 2 a, suggests compensatory upregulation of brain AA metabolism [42] . Upregulation also occurs when DHA metabolism is reduced by dietary n-3 fatty acid deprivation [43] . Increased P-cPLA 2 a protein suggests accelerated post-translational phosphorylation of cPLA 2 a serine residues [44] . COX-2 expression was reduced, although it was reported to be elevated at 4 months [21] . Expression of COX-1, which can be coupled to iPLA 2 b [45] , was unchanged.
Similar protein levels of drebrin, PSD95, synaptophysin and DAT in the 15-20 month old iPLA 2 b -/-and WT mice suggest absence of synaptic loss. On the other hand, presynaptic DAT protein is reduced in Parkinson disease [46] , and following ablation of the substantia nigra in rodent models of Parkinson disease [47] . Thus, at 15-20 months, the model does not have all the classical features of Parkinson disease. This also applies to the absence of differences in expression of Parkin (Park2) [48] and of Pink1 (Park6) [49] , which regulate mitochondrial integrity [50] . Regional changes potentially identifiable by immunocytochemistry cannot yet be excluded, especially in the substantia nigra, which is specifically impacted by dopaminergic neuronal loss in Parkinson disease. Activated microglia produce NO via iNOS, reactive oxygen species, and pro-inflammatory cytokines that might contribute to brain pathology in Parkinson disease [51, 52] . Reduced BDNF expression in the older iPLA 2 b -/-mice also suggests increased susceptibility to neuronal death [53] , which is observed in the substantia nigra of Parkinson disease patients [54] .
Brain a-synuclein mRNA was increased in the older iPLA 2 b -/-mice, consistent with reported a-synucleinpositive spheroids in the striatum of iPLA 2 b -/-mice [16] . Alpha-synuclein can activate glia [55] and is thought to -/-mice. mRNA was quantified in duplicate with Taqman Ò RT-PCR using the DDCt method and normalization to 18S expression. Results are expressed as mean ± SEM (n = 8). a-synuclein (a) and PINK1 (b) were quantified in the cytosolic fraction. Both cytosolic (c-i) and membrane (c-ii) parkin protein levels were determined. After normalization to b-actin expression (representative immunoblot is displayed), results are expressed as % of the WT mice as mean ± SEM (n = 8, n = 7 for a-synuclein WT (outlier value of 241 was removed) and for n = 7 for Pink1 due to an unquantifiable signal). Numbers in italics indicate molecular weight markers (in kDa). *P \ 0.05 (t test) promote a self-perpetuating neurotoxic process in Parkinson disease [52] . It impacts PUFA metabolism [56] and may bind long chain fatty acids [57] . On the other hand, dietary DHA supplementation was reported to promote asynuclein accumulation in a mouse model of Parkinson disease [58] .
An iPLA 2 b preference for DHA-containing phospholipid substrates is well established [4, 6, 7, 59 ], but esterified AA also can be hydrolyzed by iPLA 2 b [60, 61] . Thus, an iPLA 2 b deficiency also might influence AA release and eicosanoid formation.
In summary, life-long distortion of brain DHA content and metabolism in iPLA 2 b -/-mice is associated with lateappearing motor disturbances accompanied by microglial and astrocytic activation, disturbed expression of enzymes involved in arachidonic acid metabolism, loss of neuroprotective BDNF, and increased neuroinflammatory cytokine expression. Using these biomarkers, efficacy of dietary interventions or suppressors of oxidative stress might be tested on disease progression in this animal model, which mimics many aspects of human progressive motor diseases, including Parkinson disease.
